secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibitor Therapeutics, Inc. (INTI)
CIK:        0001042418
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0001193125-23-223590
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibitor Therapeutics expands board to 7, appoints Ronald Osman; bylaws amended
--------------------------------------------------------------------------------

- Board increased from 4 to 7 members; Ronald E. Osman appointed as non-independent director.
- Amended bylaws require stockholders holding 50% of outstanding shares to bring business at annual meetings.
- Bylaw amendment raises vote threshold to amend/repeal bylaws from majority to 66 2/3% of voting stockholders.
- Expanded CFO and Secretary roles; removed references to Amended and Restated Equity Holders Agreement.
- Mr. Osman is a licensed attorney with over 40 years of experience in False Claims Act litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042418/000119312523223590/0001193125-23-223590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042418/000119312523223590/d878120d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-223590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer